Sign In
Last checked at 
16 Sep 2025 07:00
16 September 2025
Scancell Holdings plc
("Scancell" or the "Company")
Director Dealing
Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, announces that Vulpes Testudo Fund, a fund closely associated with Martin Diggle, Non-Executive Director, has purchased 3,150,000 ordinary shares of 0.1p each ('Ordinary Shares') in the Company on 12 September 2025 at a price of 8.861 pence per share. Following the purchase, Vulpes Life Science Fund and Vulpes Testudo Fund together hold 143,537,037 ordinary shares representing 13.83% of the company.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Vulpes Testudo Fund |
2 | Reason for the notification | |
a) | Position/status | Fund closely associated with Martin Diggle, Non-Executive Director |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Scancell Holdings plc |
b) | LEI | 2138008RXEG856SNP666 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.1 pence each |
b) | Identification Code | GB00B63D3314 |
c) | Nature of the transaction | Purchase of Ordinary Shares |
d) | Price(s) and volume(s) | 8.861 pence and 3,150,000 |
e) | Aggregated information - Aggregated volume - Price |
3,150,000 Ordinary Shares 8.861 pence per Ordinary Share |
f) | Date of the transaction (s) | 12 September 2025 |
g) | Place of the transaction | London Stock Exchange, AIM |
-ENDS-
Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage biotechnology company developing targeted off-the-shelf active immunotherapies, to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, the lead product from their DNA ImmunoBody® platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their Moditope® platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, Scancell's wholly owned subsidiary, GlyMab Therapeutics Ltd., has been established with the intention to hold and develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.
For more information please contact:
Scancell Holdings plc | +44 (0) 20 3709 5700 |
Phil L'Huillier, CEO | |
Sath Nirmalananthan, CFO | |
Panmure Liberum (Nominated Adviser and Joint Broker) | +44 (0) 20 7886 2500 |
Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) | |
WG Partners LLP (Joint Broker) David Wilson, Claes Spang | +44 (0) 20 3705 9330
|
Investor and media relations Mary-Ann Chang | +44 (0) 20 7483 284853 MaryAnnChang@scancell.co.uk |
Follow the stocks
